{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:19:10Z","timestamp":1793117950324,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Esther Koplowitz Centre (CEK)"},{"name":"Spanish Ministry of Economy and Competitiveness"},{"name":"Instituto de Salud Carlos III, CIBERSAM, the Spanish Ministry of Education"},{"name":"Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group"},{"DOI":"10.13039\/100000874","name":"Brain & Behavior Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.euroneuro.2014.12.004","type":"journal-article","created":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T12:04:57Z","timestamp":1421669097000},"page":"231-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Cognition as a target in major depression: New developments"],"prefix":"10.1016","volume":"25","author":[{"given":"Brisa","family":"Sol\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Martinez-Aran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.12.004_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.11R01CR","article-title":"Pharmacological aspects of the acetylcholinesterase inhibitor galantamine","volume":"116","author":"Ago","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jad.2012.04.020","article-title":"A systematic review of cognitive remediation for schizo-affective and affective disorders","volume":"142","author":"Anaya","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/0269881111424928","article-title":"Effects of omega-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals","volume":"26","author":"Antypa","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/ajcn\/84.6.1308","article-title":"Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials","volume":"84","author":"Appleton","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3945\/ajcn.2009.28313","article-title":"Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood","volume":"91","author":"Appleton","year":"2010","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.biopsych.2004.08.019","article-title":"Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions","volume":"57","author":"Arnsten","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib7","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1038\/tp.2013.34","article-title":"Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy","volume":"3","author":"Bakermans-Kranenburg","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib8","first-page":"301","article-title":"Social effects of oxytocin in humans: context and person matter","volume":"15","author":"Bartz","year":"2011","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.psychres.2008.12.001","article-title":"The role of cognitive impairment in general functioning in major depression","volume":"176","author":"Baune","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.psychres.2014.05.013","article-title":"Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression\u2014A systematic review","volume":"219","author":"Baune","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.biopsych.2013.05.029","article-title":"Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder","volume":"74","author":"Blier","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jad.2014.02.034","article-title":"Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder","volume":"160","author":"Bonnin","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib13","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1017\/S0033291712002085","article-title":"Cognitive impairment in euthymic major depressive disorder: a meta-analysis","volume":"43","author":"Bora","year":"2013","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2012.246","article-title":"GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects","volume":"38","author":"Burgdorf","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib15","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.euroneuro.2013.04.001","article-title":"The increasing burden of mental and neurological disorders","volume":"23","author":"Catala-Lopez","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.plefa.2006.07.005","article-title":"Omega-3 fatty acids and monoamine neurotransmission","volume":"75","author":"Chalon","year":"2006","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.jcp.0000104910.75206.b9","article-title":"A prospective trial of modafinil as an adjunctive treatment of major depression","volume":"24","author":"DeBattista","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881114527361","article-title":"Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic","volume":"28","author":"Diamond","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1600-0447.2012.01910.x","article-title":"Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview","volume":"126","author":"Dias","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0165-0173(86)90016-0","article-title":"Cholinergic mechanisms in depression","volume":"396","author":"Dilsaver","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib21","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.biopsych.2012.09.031","article-title":"Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review","volume":"73","author":"Drevets","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fnhum.2013.00487","article-title":"Oxytocin and socioemotional aging: current knowledge and future trends","volume":"7","author":"Ebner","year":"2013","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/JCP.0b013e318172756c","article-title":"Galantamine as an adjunctive treatment in major depression","volume":"28","author":"Elgamal","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psyneuen.2012.06.016","article-title":"Intranasal oxytocin impedes the ability to ignore task-irrelevant facial expressions of sadness in students with depressive symptoms","volume":"38","author":"Ellenbogen","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/WNF.0b013e3180314ae7","article-title":"An open-label, flexible-dose study of memantine in major depressive disorder","volume":"30","author":"Ferguson","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib26","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archpsyc.63.10.1121","article-title":"Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial","volume":"63","author":"Furey","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2012.08.001","article-title":"Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target","volume":"64","author":"Goeldner","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.4088\/JCP.13r08560","article-title":"Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials","volume":"74","author":"Goss","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.yhbeh.2012.01.002","article-title":"A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions","volume":"61","author":"Guastella","year":"2012","journal-title":"Horm. Behav."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145712000910","article-title":"A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression","volume":"16","author":"Heresco-Levy","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib31","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jpsychires.2008.10.015","article-title":"Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder","volume":"43","author":"Herrera-Guzman","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/gps.1951","article-title":"A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression","volume":"23","author":"Holtzheimer","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.jvca.2009.05.008","article-title":"Neuroprotection by ketamine: a review of the experimental and clinical evidence","volume":"24","author":"Hudetz","year":"2010","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.psychres.2005.11.011","article-title":"Neurocognitive deficits and disability in major depressive disorder","volume":"145","author":"Jaeger","year":"2006","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jama.292.3.338","article-title":"Antidepressants and the risk of suicidal behaviors","volume":"292","author":"Jick","year":"2004","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib39","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1176\/appi.ajp.2012.12040531","article-title":"Synaptic mechanisms underlying rapid antidepressant action of ketamine","volume":"169","author":"Kavalali","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib40","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.13r08609","article-title":"Cogntive effects of pharmacotherpay for major depressive disorder: a systematic review","author":"Keefe","year":"2014","journal-title":"J. Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib41","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1997.01830160031005","article-title":"Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey","volume":"54","author":"Kessler","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1176\/jnp.15.1.27","article-title":"Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT","volume":"15","author":"Krystal","year":"2003","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0163-7258(03)00054-8","article-title":"N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability","volume":"99","author":"Krystal","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.eurpsy.2011.03.006","article-title":"Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder","volume":"27","author":"Levkovitz","year":"2012","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib46","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.4088\/JCP.v68n0712","article-title":"A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids","volume":"68","author":"Lin","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jad.2012.04.032","article-title":"Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial","volume":"142","author":"Loo","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib48","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.psyneuen.2013.05.014","article-title":"Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression","volume":"38","author":"Macdonald","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/YCT.0b013e31815ef25b","article-title":"Cognitive impairment following electroconvulsive therapy\u2014does the choice of anesthetic agent make a difference?","volume":"24","author":"MacPherson","year":"2008","journal-title":"J. ECT"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib50","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/npp.2013.334","article-title":"Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder","volume":"39","author":"Madhoo","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pnpbp.2012.10.005","article-title":"Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion","volume":"40","author":"Mah","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2014.12.004_bib200","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jpsychires.2007.06.002","article-title":"The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study","volume":"42","author":"Matthews","year":"2008","journal-title":"J Psychiatr Res."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/YCT.0b013e31828b3523","article-title":"A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy","volume":"29","author":"Matthews","year":"2013","journal-title":"J. ECT"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib53","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/schbul\/sbm014","article-title":"Development of a brief scale of everyday functioning in persons with serious mental illness","volume":"33","author":"Mausbach","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00124509-200606000-00005","article-title":"Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies","volume":"22","author":"McDaniel","year":"2006","journal-title":"J. ECT"},{"issue":"Suppl. 2","key":"10.1016\/j.euroneuro.2014.12.004_bib55","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.4088\/JCP.12084su1c.03","article-title":"Using measurement strategies to identify and monitor residual symptoms","volume":"74","author":"McIntyre","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib56","first-page":"1","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults","author":"McIntyre","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib57","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.npp.1301534","article-title":"Modafinil: a review of neurochemical actions and effects on cognition","volume":"33","author":"Minzenberg","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib58","doi-asserted-by":"crossref","first-page":"1158S","DOI":"10.1093\/ajcn\/76.5.1158S","article-title":"Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence","volume":"76","author":"Mischoulon","year":"2002","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib59","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-010-1842-7","article-title":"Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients","volume":"210","author":"Miskowiak","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib60","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/npp.2013.335","article-title":"Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"39","author":"Miskowiak","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00213-011-2511-1","article-title":"Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression","volume":"219","author":"Miskowiak","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib62","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4088\/JCP.v69n0308","article-title":"Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence","volume":"69","author":"Muhonen","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00213-004-1926-3","article-title":"Effects of modafinil on working memory processes in humans","volume":"177","author":"Muller","year":"2004","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.euroneuro.2014.12.004_bib64","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00213-013-3255-x","article-title":"Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response","volume":"231","author":"Murrough","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib65","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.291.15.1887","article-title":"Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis","volume":"291","author":"Nunes","year":"2004","journal-title":"J. Am. Med. Assoc."},{"issue":"Suppl. 5","key":"10.1016\/j.euroneuro.2014.12.004_bib66","first-page":"S18","article-title":"Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder","volume":"70","author":"Papakostas","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib67","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/appi.ajp.2009.09081198","article-title":"S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial","volume":"167","author":"Papakostas","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib68","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/gps.1958","article-title":"Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study","volume":"23","author":"Pelton","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib69","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fpsyt.2010.00134","article-title":"Inverse effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: a double-blind placebo controlled FMRI study","volume":"1","author":"Pincus","year":"2010","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.nmd.0000110280.19284.47","article-title":"Assessing past treatment history: test\u2013retest reliability of the Treatment Response to Antidepressant Questionnaire","volume":"192","author":"Posternak","year":"2004","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib71","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib72","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.psychres.2013.12.027","article-title":"A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy","volume":"215","author":"Rasmussen","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archgenpsychiatry.2010.184","article-title":"Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy","volume":"68","author":"Reynolds","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib74","first-page":"1","article-title":"Cognitive impairment in depression: a systematic review and meta-analysis","author":"Rock","year":"2013","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib75","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S0007114507801097","article-title":"No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial","volume":"99","author":"Rogers","year":"2008","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jad.2013.02.022","article-title":"Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA)","volume":"150","author":"Rosa","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1745-0179-3-5","article-title":"Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder","volume":"3","author":"Rosa","year":"2007","journal-title":"Clin. Pract. Epidemol. Ment. Health"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib78","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1176\/appi.ajp.2011.10111645","article-title":"Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study","volume":"168","author":"Rush","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2014.12.004_bib79","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib80","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrd2462","article-title":"Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders","volume":"7","author":"Sanacora","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib81","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence","volume":"26","author":"Sani","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib82","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1586\/ern.09.52","article-title":"Hypothalamic\u2013pituitary\u2013adrenocortical system dysregulation and new treatment strategies in depression","volume":"9","author":"Schule","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib83","first-page":"1","article-title":"Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression","author":"Shiroma","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib84","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","article-title":"Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system","volume":"6","author":"Siren","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib85","doi-asserted-by":"crossref","first-page":"966","DOI":"10.4088\/JCP.12m08252","article-title":"Antidepressant augmentation using the N-methyl-d-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial","volume":"74","author":"Smith","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(14)70697-2","article-title":"Functional remediation for patients with bipolar II disorder: improvement of functioning and subsyndromal symptoms","author":"Sole","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl. 6","key":"10.1016\/j.euroneuro.2014.12.004_bib87","first-page":"S16","article-title":"Treatment-resistant depression","volume":"67","author":"Souery","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 13","key":"10.1016\/j.euroneuro.2014.12.004_bib88","first-page":"S13","article-title":"Differences in mechanism of action between current and future antidepressants","volume":"64","author":"Stahl","year":"2003","journal-title":"J. Clin .Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib89","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/08039488.2011.626870","article-title":"Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?","volume":"66","author":"Svendsen","year":"2012","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib90","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1176\/appi.ajp.2012.12070971","article-title":"Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study","volume":"170","author":"Torrent","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib91","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4088\/JCP.13m08360","article-title":"A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram","volume":"74","author":"Trivedi","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\u204eD: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib93","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/07853890.2011.583675","article-title":"Therapeutic options in treatment-resistant depression","volume":"43","author":"Vieta","year":"2011","journal-title":"Ann. Med."},{"key":"10.1016\/j.euroneuro.2014.12.004_bib94","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.biopsych.2012.05.029","article-title":"A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression","volume":"72","author":"Watson","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib95","series-title":"Depression: A Global Public Healrth Concern","author":"WHO","year":"2012"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib96","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/YCT.0b013e3182a4b4c6","article-title":"Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study","volume":"30","author":"Yoosefi","year":"2014","journal-title":"J. ECT"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib97","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/sj.npp.1300471","article-title":"Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder","volume":"29","author":"Young","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib98","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","article-title":"A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression","volume":"74","author":"Zarate","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib99","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.12.004_bib100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","article-title":"A double-blind, placebo-controlled study of memantine in the treatment of major depression","volume":"163","author":"Zarate","year":"2006","journal-title":"Am. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14003514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14003514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:51:08Z","timestamp":1760377868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14003514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0924977X14003514"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.12.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognition as a target in major depression: New developments","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}